Emma Andrus, Associate Editor

The organizations called for skin health to be considered a global public health priority in a recent side meeting at the World Health Assembly.

Researchers compared the examination's content outline with data on skin diseases in a recent study.

Review our coverage and expert interviews from the recent Society of Dermatology Physician Assistants' annual summer meeting.

Aubrie Jones, PA-C, MMS, and Laura Bush, DMSc, PA-C, DFAAPA, discuss the role of the SDPA in supporting the growth and journeys of PAs at all stages.

Today, June 13, is the 10th annual International Albinism Awareness Day.

LEO Pharma's Adbry, a single-dose autoinjector, is expected to become available to patients in the coming months.

Gottlieb reviews her lecture from the Society for Investigative Dermatology Annual Meeting.

Ahead of the next 3 months of the year, Dermatology Times wants to know what conferences and meetings you plan to attend between July and September. Share your thoughts with us by June 26.

Conversely, there were higher levels of selenium and folic acid detected in patients with vitiligo versus otherwise healthy individuals.

Kristine Kucera, PA-C, MPAS, DHS, discusses the atopic dermatitis patient experience alongside one of her patients, Mickey Bryson.

The phase 3 IZAR program will evaluate the efficacy and safety of sonelokimab in patients with psoriatic arthritis for a 1 year duration.

Data from the TRuE-V mechanism of action study was presented in a poster at the 2024 RAVE Conference.

Henry Lim, MD, discusses key findings and areas of improvement identified by the report, as well as his hopes for HS treatment moving forward.

Turn Therapeutics' Bradley Burnam recently spoke with Dermatology Times.

These findings may provide guidance for future international definitions of degrees of activity and repigmentation in vitiligo.

UCB recently announced phase 3 BE HEARD I and II trial results on bimekizumab for treating moderate to severe HS were published in The Lancet.

Dermatology Times asked our readers to share what conferences they are looking forward to in the second quarter of 2024.

Keep up with the latest headlines in dermatology from the past week, including US sunscreen versus global regulations, all-time high melanoma rates in the UK, and more.

Earlier this week, we shared our fourth and final Skin Cancer Awareness Month quiz. Review the answers and your responses below.

Dermatology Times is looking back on the top stories in dermatology from the month of May.

Novartis announced late-breaking data for the BTK inhibitor at the 2024 European Academy of Allergy and Clinical Immunology Congress.

At the conclusion of this year's Mental Health Awareness Month, we recap our coverage of the latest studies and research exploring the effects of skin on mental health.

May is Asian American and Pacific Islander Heritage Month. We review articles from the past month spotlighting dermatologic concerns in this patient population.

Miranti previews her sessions from the meeting which kicks off tomorrow, May 30, in Orlando, Florida.

Hadar Lev-Tov, MD, MAS, President of the HS Foundation, discusses the organization's hopes for the future and upcoming efforts.

Supportive data for roflumilast in adults and children 6 years of age and older stems from the INTEGUMENT studies.

Based on these findings, Innovent plans to submit a New Drug Application to the Center for Drug Evaluation of National Medical Product Administration.

Click here to read more and answer our quiz questions in recognition of Skin Cancer Awareness Month.

Keep up with the latest headlines in dermatology from the past week, including exposure to UV light and its implications for metabolism, the effects of skin conditions on children, and more.

Supplementation with RGLE led to clinically significant improvements in patients with acne vulgaris, according to a study.